To evaluate the clinical efficacy and safety of bevacizumab in treating patients with hereditary hemorrhagic telangiectasia who suffer from severe hepatic vascular malformations and elevated cardiac output.
Interventional clinical trial registered under clinicaltrials.gov identifier NCT00843440.
Evaluated the administration of bevacizumab in individuals diagnosed with hereditary hemorrhagic telangiectasia with documented hepatic vascular malformations.
Clinical outcomes assess the antiangiogenic effect of bevacizumab on reducing hepatic vascular shunting and hyperdynamic cardiac states.
Safety and hemodynamic efficacy endpoints are documented in trial registry NCT00843440.